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ABSTRACT: The fully O-sulfated, O-methylated, heparin-related, anticoagulant pentasaccharide idraparinux was prepared by a 
new synthetic pathway in 38 steps using D-glucose and methyl α-D-glucopyranoside as starting materials, with 23 steps for the 
longest linear route. The L-idose-containing GH fragment was obtained by a short and straightforward synthesis whereby a 4,6-
cyclic-acetal-protected L-idosyl thioglycoside bearing a C2-nonparticipating group was used as the -selective glycosyl donor. The 
novel L-idose donor was prepared with high chemo- and stereoselectivity by hydroboration–oxidation-based C5 epimerization 
starting from an orthogonally protected -thioglucoside. The assembly of the pentasaccharide backbone was achieved by an F+GH 
and DE+FGH coupling sequence with full stereoselectivity in each glycosylation step. 
INTRODUCTION 
Heparin polysaccharide and its smaller fragments are invalua-
ble drugs in the prevention and treatment of thromboembolic 
diseases owing to their anticoagulant properties.
1
 Heparin 
binds to and activates antithrombin which, in turn, inhibits 
blood coagulation factors IIa and Xa.
2
 Characterization of the 
shortest heparin sequence able to activate antithrombin, the 
DEFGH pentasaccharide 1, along with SAR studies led to the 
synthetic antithrombotic drug fondaparinux (Arixtra, 2), pos-
sessing selective factor Xa inhibitory activity by means of 
activation of antithrombin
3
 (Figure 1). The lengthy and de-
manding synthesis of fondaparinux
4
 spurred research to design 
simplified analogues easier to prepare. The replacement of 
glucosamine by glucose units and the introduction of methyl 
ethers to hydroxyls on non-crucial positions resulted in the 
discovery of non-glycosaminoglycan derivatives such as 
idraparinux (3)
3,5
 which is an extremely potent heparinoid 
antithrombotic. Idraparinux binds to antithrombin significantly 
stronger than fondaparinux through the additional interaction 
of the extra sulfate group of the H glucose unit as well as 
through hydrophobic interactions. The potency of idraparinux 
is associated with its long half-life which allows a convenient 
once-a-week administration in humans. However, in the lack 
of neutralizing agent, the long elimination half-life proved to 
be a double-edged sword, and the development of idraparinux 
was stopped due to major bleeding events during treatment for 
more than six months.
6 
Recently, new antidotes have emerged in the anticoagulant 
therapy.
7
 Andexanet alfa, a recombinant protein designed as a 
specific reversal agent against both direct and indirect factor 
Xa inhibitors, was approved by FDA in 2018.
8
 Aripazine 
(ciraparantag), a synthetic small cationic compound is another, 
clinically investigated reversal agent with promising activity 
against heparinoid anticoagulants.
9
 These new results might 
attract renewed interest toward idraparinux. 
Despite the simplified structure, the synthesis of idraparinux 
still poses challenges like the efficient synthesis of the L-idosyl 
building block as well as the introduction of methyl ethers 
onto the uronic acid residues which are prone to suffer β-
elimination under basic conditions of the etherification. 
 
Figure 1. Structure of the AT-binding pentasaccharide domain of 
heparin (1) and the synthetic anticoagulant pentasaccharides 
fondaparinux (2) and idraparinux (3) 
In most syntheses, orthogonally protected 2-O-acyl L-
idopyranose or L-iduronic acid building block is prepared from 
D-glucose via various lengthy procedures
10
 and used as a C2-
participating glycosyl donor (Scheme 1, A). The 2-O-acyl 
group ensures the required 1,2-trans stereoselectivity upon 
glycosylation, however, its change into methyl ether further 
lengthen the synthesis at an oligosaccharide level.
5,11-14
 Re-
cently, Lopatkiewicz and co-workers established a 
nonglycosylating chemical strategy for the synthesis of 
idraparinux in which the GH and EF disaccharide units were 
prepared from the same cellobiose (Scheme 1, B).
15
 They 
introduced the needed methyl ethers at an early stage of the 
synthesis and the functionalized cellobiose was transformed to 
the GH unit via epimerization of C5’ by an elimination-
addition sequence. The synthesis of fully protected idraparinux 
was significantly shortened and improved by this imaginative 
approach which still has  
  
 
Scheme 1. Synthetic strategies toward the GH fragment of idraparinux 
 
 
weaknesses such as the low efficacy of the C5’ epimerization 
step as well as the low stereoselectivity during conversion of 
the 1,6-anhydro ring of unit H into methyl α-glycoside. 
Very recently, we published a straightforward new synthesis 
of L-idosyl glycosyl donors starting from orthogonally protect-
ed α-thioglucosides.
16
 The key steps include C5 epimerization 
by hydroboration/oxidation of the corresponding 5-
enopyranosides followed by a 4,6-O-acetal formation of the 
obtained L-idosides. We demonstrated in model glycosylations 
of a GlcNAc acceptor that the 4,6-arylmethylene acetal en-
sures full 1,2-trans α-selectivity in the absence of a participat-
ing group at C2 position. On the basis of these results we 
envisioned a significantly shortened route to idraparinux by 
applying a 2,3-di-O-methylated L-idosyl donor for the synthe-
sis of the GH fragment. 
RESULTS AND DISCUSSION 
We have developed an efficient synthetic strategy for 
idraparinux
14
 and related pentasaccharides
17,18
 which was 
based on the coupling of an FGH acceptor and a DE donor, 
both containing a non-oxidized precursor of the hexuronic acid 
unit, and formation of the uronic acids was performed in one 
step at the pentasaccharide level. While keeping this post-
glycosylation oxidation strategy,
19
 we devised a significantly 
shortened synthesis for the GH building block by utilizing a 
new, non-participating L-idosyl glycosyl donor which is readi-
ly available from a suitably protected α-thioglucoside by our 
recent method.
16
 
The synthesis of the starting α-thioglucoside 4
20 
was accom-
plished by stereoselective introduction of the ethylthio aglycon 
to 2-acetoxy-D-glucal by photoinduced hydrothiolation
21,22
 
followed by deacetylation and 4,6-O-(2-
naphthyl)methylenation. The methyl ether functions of the 
final product were introduced into positions 2 and 3 at this 
early stage of synthesis to give 5 in 92% yield. Next, the 
regioselective ring opening of the 4,6-O-(2-
naphthyl)methylene acetal using the LiAlH4-AlCl3 reagent 
combination in a 3:1 ratio
23
 resulted in compound 6 in an 
excellent 90% yield. Subsequent substitution of the 6-OH 
group with iodine gave 7 in 84% yield. It is worth mentioning 
that each compound of this reaction sequence was obtained in 
crystalline form (Scheme 2). 
Scheme 2. Synthesis of the 6-deoxy-6-iodo-α-thioglucoside 
derivative 7
a
 
 
aReagents and conditions: i) dry DMF, NaH, 0 °C to rt, 24h 
(92%); ii) dry CH2Cl2, dry Et2O, LiAlH4, AlCl3, rt, 1h (90%); iii) 
dry toluene, PPh3, I2, imidazole, 75 °C, 30 min (84%); Np: 2-
naphthyl; NAP: (2-naphthyl)methyl. 
Conversion of 7 into the L-idoside derivative 8 was carried out 
by the well-established C5-epimerization method including 
NaH-mediated elimination, hydroboration using BH3·THF and 
oxidation with H2O2 under basic conditions.
24,25
 
While this reaction sequence had proceeded both in high yield 
and high stereoselectivity starting from 2,3-di-O-benzyl α-
 thioglucosides,
16
 upon dehydrohalogenation of the 2,3-di-O-
methylated 7 with sodium hydride a number of byproducts 
were observed by TLC and, after hydroboration/oxidation, the 
expected L-idose derivative 8 was only formed in low 41% 
yield (Scheme 3, Route A). Thus, we attempted to produce the 
5,6-unsaturated 7a derivative by another method using silver 
fluoride in dry pyridine (Scheme 3., Route B). To our great 
satisfaction, the AgF-mediated elimination provided cleanly 
the 6-deoxy-α-D-xylo-hex-5-enopyranoside 7a which was 
subjected directly to hydroboration-oxidation to produce the 
desired L-idose derivative 8 in a good yield of 66% over three 
steps (87% per step). As we expected, the α-anomeric configu-
ration of 7a ensured the required high L-ido selectivity in the 
hydroboration step and the D-gluco epimer by-product 6 was 
formed only in a negligible amount. Moreover, the oxidation 
occurred with high chemoselectivity indicated by the small 
extent of overoxidized by-product 9. (The structure of 6 and 9 
was identified on the basis of the MS data and NMR spectra of 
their inseparable mixture.) The observed high stereo- and 
chemoselectivity of the hydroboration/oxidation of the α-
thioglycoside is in line with our previous results.
16
 A third by-
product, the 6-fluoro derivative (10) of the initial glucose 
compound was also isolated from the reaction mixture in an 
11% yield. It must have been formed during the elimination 
reaction, but could not be distinguished by TLC from the 5,6-
unsaturated derivative. 
Scheme 3. The elimination and epimerization reactions of 
compound 7
a
 
 
aReagents and conditions: i) dry DMF, NaH, 0 °C to rt, 24h; ii) 
dry THF, BH3·THF, 0 °C, 1.5h; iii) 30% H2O2, 2M NaOH, 0 °C 
to rt, 50 min; iv) dry pyr., AgF, rt, 24h. 
Next, compound 8 was converted to the corresponding 4,6-O-
(2-napthyl)methylene derivative 11 by oxidative ring closure 
with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 
(Scheme 4). It was followed by the key step of the synthesis, 
glycosylation of monosaccharide acceptor 12
26
 with the new, 
non-participating L-idosyl donor 11. We demonstrated earlier 
that glycosylation reaction between the 2,3-di-O-benzyl con-
gener of 11 and a GlcNAc acceptor of low reactivity proceed-
ed with full 1,2-trans α-selectivity.
16
 However, it was ques-
tionable whether donor 11 was able to ensure complete 
stereoselectivity when reacting with an acceptor of higher 
reactivity. To our great delight, condensation of acceptor 12 
and donor 11 upon iodonium ion activation resulted in the 
desired α-linked GH disaccharide with full stereoselectivity in 
high yield and in crystalline form. The exclusive α-
stereoselectivity can be explained by the steric hinderence of 
the C2-protecting group to prevent nucleophilic attack from 
the β-face and by the controlling effect of the 4,6-O-cyclic 
protecting group which has been demonstrated to ensure α-
selectivity in D-glucosylation and D-galactosylation reac-
tions.
27,28 
Conversion of the fully protected disaccharide 13 to an accep-
tor by regioselective ring opening reaction was first attempted 
with a BF3·Et2O-Et3SiH
29
 reagent combination. Unfortunately, 
the main product of the reaction was diol 15 and the expected 
6’-ether 14 was only formed in a low 20% yield. Hence, we 
turned to the Me3N·BH3-AlCl3 reagent system which is known 
to cleave the 4,6-O-acetals with a solvent dependent 
regioselectivity.
26,30
 In THF, the required 4’-OH/6’-O-ether 14 
was isolated as the only product in 80% yield. Diol 15 was 
also converted to a disaccharide acceptor building block by 
regioselective silylation of the primary hydroxyl group. 
Treatment of 15 with tert-butyldiphenylsilyl chloride 
(TBDPSCl) in dry pyridine provided acceptor 16 in excellent 
yield. 
Scheme 4. Preparation of GH disaccharide 13 and its 
transformations to acceptors 14 and 16
a
 
 
aReagents and conditions: i) dry CH2Cl2, DDQ, 0 °C, 50min 
(67%); ii) dry CH2Cl2, NIS, AgOTf, −40 to −20 °C, 4h (72%); iii) 
dry CH2Cl2, Et3SiH, BF3·Et2O, 0 °C to rt, 2 h (14: 20%, 15: 42%); 
iv) dry THF, BH3·Me3N, AlCl3, rt, 1 h (only 14, 80%); v) dry 
pyr., TBDPSCl, rt, 24h (81%). 
Glycosylation of disaccharide 16 with thioglycoside donor 
17
31
 upon iodonium ion activation resulted in FGH 
trisaccharide 18 with the desired α-interglycosidic linkage in 
88% yield (Scheme 5.). Conversion of 18 to acceptor 19a was 
achieved again by a regioselective ring-opening reaction using 
the Me3N·BH3-AlCl3 reagent system in THF to produce the 
desired product in 63% yield along with the regioisomeric by-
product 19b isolated in 21%. Following the above reaction 
 path, the 6’-ONAP-containing 14 was converted to another 
trisaccharide acceptor, compound 21a, with similar efficacy. 
The assembly of the non-oxidized precursor of the final prod-
uct idraparinux was initially carried out by glycosylation of 
trisaccharide acceptor 19a with the non-glucuronide type DE 
disaccharide donor 22
32 
(Scheme 6). Surprisingly, condensa-
tion of disaccharide 22 and trisaccharide 19a upon NIS-
AgOTf activation provided the DEH trisaccharide 24 as the 
major product in 46% yield, and the needed pentasaccharide 
23 was formed in a very low yield of 11%. 
Scheme 5. Synthesis of the FGH disaccharide acceptors 
19a and 21a
a
 
 
aReagents and conditions: i) dry CH2Cl2, NIS, AgOTf, −40 to 
−20 °C, 4h (18: 88%, 20: 80%); ii) dry THF, BH3·Me3N, AlCl3, 0 
°C to rt, 2.5h (19a: 65%, 19b: 21%, 21a: 70%, 21b: 19%). 
Scheme 6. Synthesis of the protected pentasaccharide 23 
by applying the silyl-containing acceptor 19a
a
 
 
aReagents and conditions: i) dry CH2Cl2, NIS, AgOTf, −20 to 
+5 °C, 4h (23: 11%, 24: 46%). 
The formation of trisaccharide 24 can be explained either by 
direct attack of the α-L-idosyl glycosidic oxygen onto the 
anomeric carbon of the dioxolenium ion formed from 22 or by 
an intramolecular glycosyl transfer reaction via the orthoester 
intermediate 23a (Scheme 7). The intermolecular glycosyl 
transfer to 22a could only occur if 19a adopts a conformation 
in which the free hydroxyl group is extremely shielded thereby 
the attack of the interglycosidic oxygen, nucleophilicity of 
which is enhanced by the surrounding electron-donating ether 
substituents, becomes dominant. Another, more probable 
mechanism is the formation of orthoester 23a which then can 
undergo either a conventional rearrangement to give the ex-
pected pentasaccharide 23 or can be transformed to 
trisaccharide 24 by intramolecular transfer of unit H onto the 
glycosidic center of unit E. 
Scheme 7. Plausible mechanism of the formation of DEH 
trisaccharide 24 
 
In the hope of a more efficient synthesis of the protected 
pentasaccharide skeleton, disaccharide 22 was reacted with the 
NAP-group-containing disaccharide acceptor 21a upon NIS-
TfOH activation. This case the [2+3] coupling reaction pro-
ceeded with high efficacy to provide the expected protected 
pentasaccharide 25 with complete β-stereoselectivity, in 70% 
yield (Scheme 8). 
Scheme 8. The [2+3] coupling reaction with the NAP-
containing trisaccharide acceptor 21a
a
 
 
aReagents and conditions: i) dry CH2Cl2, NIS, TfOH, −20 to +5 
°C, 4h (70%). 
The synthesis was continued with the NAP-containing 
pentasaccharide 25 of which we had a sufficient amount for 
 the remaining transformations (Scheme 9). First, compound 
25 was subjected to Zemplén deacetylation to produce diol 26. 
Introduction of the methyl ethers to the freed hydroxyls was 
accomplished by standard alkylation using methyl iodide and 
sodium hydride to afford the desired compound 27 in 80% 
yield. Next, the primary hydroxyls that were to be oxidized in 
units E and G were liberated in one step by oxidative cleavage 
of the NAP groups with DDQ
33
 to provide diol 28
14
 in 70% 
yield. The final transformations of 28 into idraparinux, involv-
ing TEMPO-BAIB-mediated oxidation, removal of benzyl 
ethers by catalytic hydrogenation and O-sulfation using 
SO3·Et3N, were performed according to our previous meth-
od.
14
 
Scheme 9. The transformation of the 6-O-NAP containing 
protected pentasaccharide
a
 
 
 
aReagents and conditions: i) MeOH, NaOMe, rt, 24h (78%); ii) 
dry DMF, NaH, 0 °C to rt, 24h (80%); iii) CH2Cl2, H2O, DDQ, rt, 
30min (71%). 
CONCLUSION 
We have developed a new approach to the synthesis of 
idraparinux in which the novel and efficient preparation of a 
4,6-O-acetal-containing L-idose donor and its utilization for 
the synthesis of the GH disaccharide fragment were the key 
steps. The synthesis of the new idosyl donor was achieved 
from a properly protected -thioglucoside in four steps includ-
ing AgF-mediated elimination, stereoselective hydroboration 
using BH3·THF, chemoselective oxidation with H2O2 and 
DDQ-mediated oxidative acetal ring-closure. By applying this 
donor, due to the controlling effect of the 4,6-acetal group, the 
GH building block was prepared with full 1,2-trans-α-
stereoselectivity in the absence of a participating group at C2 
position. Tipically, L-idose or L-iduronic acid donors with a 
C2 participating group have been applied for the construction 
of the -L-idosyl glycosidic linkage.
10,34
 The demonstrated -
stereodirecting effect of the 4,6-cyclic acetal in the presence of 
an ether protecting group at C2 position pave the way to de-
signing new, more diverse protecting group strategies for the 
synthesis of heparin and heparin sulfate oligosaccharides. 
Another advantage of this new approach to GH unit is that 
most synthetic intermediates were obtained in crystalline form. 
The idopyranosyl-containing GH unit was successfully incor-
porated to a late-stage oxidation strategy whereby the non-
oxidized pentasaccharide backbone was created by an F+GH 
and DE+FGH coupling sequence, with full stereoselectivity in 
each glycosylation step, followed by simultaneous formation 
of two carboxylic functions at the pentasaccharide level. By 
this strategy the target pentasaccharide 3 could be achieved in 
a 38-step synthesis starting from D-glucose and methyl α-D-
glucopyranoside with 23 steps for the longest linear route. To 
the best of our knowledge, shorter route to idraparinux has not 
been described hitherto.  
 
EXPERIMENTAL SECTION 
General Information. Optical rotations were measured at 
room temperature on a Perkin–Elmer 241 automatic 
polarimeter. TLC analysis was performed on Kieselgel 60 F254 
(Merck) silica–gel plates with visualization by immersing in a 
sulfuric-acid solution (5% in EtOH) followed by heating. 
Column chromatography was performed on silica gel 60 
(Merck 0.063–0.200 mm) and Sephadex LH-20 (Sigma–
Aldrich, bead size: 25–100 mm). Organic solutions were dried 
over MgSO4 and concentrated under vacuum. 
1
H and 
13
C 
NMR spectroscopy (
1
H: 400 and 500 MHz; 
13
C: 100.28 and 
125.76 MHz) were performed on Bruker DRX-400 and Bruker 
Avance II 500 spectrometers at 25 °C. Chemical shifts are 
referenced to SiMe4 or sodium 3-(trimethylsilyl)-1-
propanesulfonate (DSS, δ = 0.00 ppm for 
1
H nuclei) and to 
residual solvent signals (CDCl3: δ = 77.00 ppm, CD3OD: δ = 
49.15 ppm for 
13
C nuclei). MALDI-TOF MS analyses of the 
compounds were carried out in the positive reflektron mode 
using a BIFLEX III mass spectrometer (Bruker, Germany) 
equipped with delayed-ion extraction. 2,5-Dihydroxybenzoic 
acid (DHB) was used as matrix and F3CCOONa as cationising 
agent in DMF. ESI-TOF MS spectra were recorded by a 
microTOF-Q type QqTOFMS mass spectrometer (Bruker) in 
the positive ion mode using MeOH as the solvent. Elemental 
analysis was performed on an Elementar Vario MicroCube 
(CHNS) instrument. 
Ethyl 2,3-di-O-methyl-4,6-O-(2-naphthyl)methylene-1-thio-
α-D-glucopyranoside (5). Compound 4
20
 (540 mg, 1.766 
mmol) was dissolved in dry DMF (8.0 mL) and NaH (60%, 
170 mg, 4.238 mmol, 1.2 equiv./OH) was slowly added to the 
solution at 0 °C. After stirring for 30 min at 0 °C, MeI (275 
µL, 4.415 mmol, and 1.25 equiv./OH) was added. When com-
plete conversion of the starting material into a main spot had 
been observed by TLC analysis (24 h at room temperature), 
CH3OH (2.5 mL) was added. The reaction mixture was stirred 
for 5 min and the solvents were evaporated. The residue was 
dissolved in CH2Cl2 (100 mL), and washed with H2O (2 x 35 
mL), the organic layer was dried, filtered and evaporated. The 
crude product was purified by column chromatography (7:3 n-
hexane/acetone) to give 5 (634 mg, 92%) as white crystals. 
[α]D
25
 +203.6 (c 0.14, CHCl3); M.p.: 145-147 °C (EtOAc/n-
hexane); Rf 0.43 (7:3 n-hexane/acetone); 
1
H NMR (CDCl3, 
500 MHz) δ 7.97-7.47 (m, 7H, arom), 5.70 (s, 1H, Hac), 5.54 
(d, J = 4.9 Hz, 1H, H-1), 4.34-4.28 (m, 2H, H-5, H-6a), 3.83-
3.79 (m, 1H, H-6b), 3.64 (s, 3H, OCH3), 3.61-3.56 (m, 3H, H-
2, H-3, H-4), 3.52 (s, 3H, OCH3), 2.65-2.54 (m, 2H, 
SCH2CH3), 1.31 (t, J = 7.4 Hz, 3H, SCH2CH3) ppm; 
13
C NMR 
(CDCl3, 125 MHz) δ 134.8, 133.8, 133.0 (3C, 3 x Cq arom), 
 128.5-123.9 (7C, arom), 101.8 (1C, Cac), 83.8 (1C, C-1), 82.4, 
81.4, 80.3 (3C, C-2, C-3, C-4), 69.1 (1C, C-6), 62.9 (1C, C-5), 
61.3, 58.6 (2C, 2 x OCH3), 24.0 (1C, SCH2CH3), 14.9 
(SCH2CH3) ppm; MS (MALDI-TOF): m/z calcd for 
C21H26NaO5S: 413.139 [M+Na]
+
; found: 413.284; Elemental 
analysis calcd (%) for C21H26O5S: C, 64.59; H, 6.71; S, 8.21; 
found: C, 64.65; H, 6.76; S, 8.25. 
Ethyl 2,3-di-O-methyl-4-O-(2-naphthyl)methyl-1-thio-α-D-
glucopyranoside (6). To a stirred solution of the 4,6-O-acetal 
derivative 5 (1.53 g, 3.918 mmol) in a mixture of dry CH2Cl2 
(44 mL) and dry Et2O (18 mL) were added successively 
LiAlH4 (669 mg, 17.631 mmol, 4.5 equiv.) and a solution of 
AlCl3 (784 mg, 5.877 mmol, 1.5 equiv.) in dry Et2O (11 mL) 
under argon at 0 °C. When the TLC (6:4 n-hexane/EtOAc) 
indicated complete disappearance of the starting material (1 
h), the reaction mixture was cooled in an ice-bath, and the 
excess of reagent was decomposed by careful addition of 
EtOAc (79 mL) followed by H2O (19 mL), and the stirring 
was continued for additional 5 min. The mixture obtained, 
consisting of a grey, non-filterable suspension and a clear 
organic phase, was poured into a separating funnel and diluted 
with EtOAc (200 mL). The layers were separated and the 
organic phase was washed with H2O (3 x 50 mL), dried over 
MgSO4 and concentrated. The residue was purified by column 
chromatography (6:4 n-hexane/EtOAc) to give 6 (1.38 g, 90%) 
as white crystals. [α]D
25
 +230.0 (c 0.10, CHCl3); M.p.: 103-
105 °C (EtOAc/n-hexane); Rf 0.43 (7:3 n-hexane/acetone); 
1
H 
NMR (CDCl3, 400 MHz) δ 7.84-7.44 (m, 7H, arom), 5.48 (d, J 
= 5.1 Hz, 1H, H-1), 5.03 (d, J = 11.4 Hz, 1H, NAP-CH2a), 4.83 
(d, J = 11.4 Hz, 1H, NAP-CH2b), 4.09 (dt, J = 3.3 Hz, J = 8.9 
Hz, 1H, H-5), 3.83-3.73 (m, 3H), 3.66, 3.50 (2 x s, 6H, 2 x 
OCH3), 3.57-3.47 (m, 2H), 2.61-2.50 (m, 2H, SCH2CH3), 1.74 
(t, 1H, H-6-OH), 1.28 (t, J = 7.4 Hz, 3H, SCH2CH3) ppm; 
13
C 
NMR (CDCl3, 100 MHz) δ 135.8, 133.4, 133.1 (3C, 3 x Cq 
arom), 128.3-126.1 (7C, arom), 84.3 (1C, C-1), 82.8, 82.0, 
77.5, 71.1 (4C, skeleton carbons), 75.0 (1C, NAP-CH2), 62.1 
(1C, C-6), 61.3, 58.3 (2C, 2 x OCH3), 24.0 (1C, SCH2CH3), 
14.8 (1C, SCH2CH3) ppm; MS (MALDI-TOF): m/z calcd for 
C21H28NaO5S: 392.166 [M+Na]
+
; found: 392.295; Elemental 
analysis calcd (%) for C21H28O5S: C, 64.26; H, 7.19; S, 8.17; 
found: C, 64.31; H, 7.24; S, 8.24. 
Ethyl 6-deoxy-6-iodo-2,3-di-O-methyl-4-O-(2-
naphthyl)methyl-1-thio-α-D-glucopyranoside (7). To the 
solution of thioglucoside 6 (419 mg, 1.068 mmol) in dry tolu-
ene (6.3 mL), triphenylphosphine (420 mmol, 1.602 mmol, 1.5 
equiv.), imidazole (218 mg, 3.204 mmol, 3.0 equiv.) and io-
dine (387 mg, 1.495 mmol, 1.4 equiv.) were added. The reac-
tion mixture was stirred at 75 °C for 30 min then cooled to 
room temperature. To the stirred mixture NaHCO3 (210 mg) in 
water (2.6 mL) was added at room temperature. After 5 min 
10% aqueous solution of Na2S2O3 (5.0 mL) was added and the 
mixture was diluted with EtOAc (125 mL) and washed with 
H2O (2 x 35 mL). The organic layer was separated, dried over 
MgSO4 and concentrated under reduced pressure. The crude 
product was purified by column chromatography (8:2 n-
hexane/EtOAc) to give 7 (450 mg, 84%) as white crystals. 
[α]D
25
 +146.0 (c 0.40, CHCl3); M.p.: 82-84 °C (EtOAc/n-
hexane); Rf 0.41 (8:2 n-hexane/EtOAc); 
1
H NMR (CDCl3, 400 
MHz) δ 7.85-7.45 (m, 7H, arom), 5.50 (d, J = 4.7 Hz, 1H, H-
1), 5.08 (d, J = 11.2 Hz, 1H, NAP-CH2a), 4.88 (d, J = 11.2 Hz, 
1H, NAP-CH2b), 3.87-3.83 (m, 1H, H-5), 3.64, 3.50 (2 x s, 6H, 
2 x OCH3), 3.55-3.53 (m, 2H, H-2, H-3), 3.49-3.47 (m, 1H, H-
6a), 3.40 (dd, J = 5.5 Hz, J = 10.7 Hz, 1H, H-6b), 3.34 (t, J = 
8.8 Hz, 1H, H-4), 2.69-2.58 (m, 2H, SCH2CH3), 1.29 (t, J = 
7.4 Hz, 3H, SCH2CH3) ppm; 
13
C NMR (CDCl3, 100 MHz) δ 
135.7, 133.4, 133.1 (3C, 3 x Cq arom), 128.4-126.0 (7C, 
arom), 84.0 (1C, C-2), 82.6 (1C, C-1), 81.9 (1C, C-3), 81.5 
(1C, C-4), 75.3 (1C, NAP-CH2), 69.4 (1C, C-5), 61.2, 58.2 
(2C, 2 x OCH3), 24.0 (1C, SCH2CH3), 14.8 (1C, SCH2CH3), 
8.2 (1C, C-6) ppm; MS (MALDI-TOF): m/z calcd for 
C21H27INaO4S: 525.057 [M+Na]
+
; found: 525.169; Elemental 
analysis calcd (%) for C21H27IO4S: C, 50.20; H, 5.42; S, 6.38; 
found: C, 50.24; H, 5.46; S, 6.42. 
Ethyl 2,3-di-O-methyl-4-O-(2-naphthyl)methyl-1-thio-β-L-
idopyranoside (8), ethyl 2,3-di-O-methyl-4-O-(2-
naphthyl)methyl-1-thio-β-L-idopyranoside sulfoxide (9) 
and ethyl 6-deoxy-6-fluoro-2,3-di-O-methyl-4-O-(2-
naphthyl)methyl-1-thio-α-D-glucopyranoside (10). Method 
I.: A vigorously stirred solution of iodide 7 (1.38 g, 2.746 
mmol) in dry DMF (23 mL) was cooled to 0 °C, NaH (132 
mg, 5.494 mmol, 2.0 equiv.) was added and the reaction mix-
ture was stirred at room temperature for 24 h. After the com-
plete disappearance of the starting material, MeOH (2.0 mL) 
was added and the mixture was concentrated. The residue was 
dissolved in CH2Cl2 (250 mL) and washed with H2O (2 x 50 
mL). The organic layer was separated, dried over MgSO4 and 
concentrated under reduced pressure. To a stirred solution of 
the crude product (954 mg, 2.548 mmol) in anhydrous THF 
(6.5 mL) a solution of BH3·THF complex in THF (1M, 25.5 
mL, 25.487 mmol, 10.0 equiv.) was added at 0 °C. The reac-
tion mixture was kept at this temperature for 1.5 h. Then H2O2 
(30%, 6.5 mL) and an aqueous solution of NaOH (2M, 13.5 
mL) were added at 0 °C and the reaction mixture was stirred at 
room temperature for 50 min. Subsequently, the reaction mix-
ture was diluted with EtOAc (150 mL) and washed with satu-
rated aqueous solution of NH4Cl (2 x 25 mL), H2O (25 mL) 
and brine (25 mL). The organic layer was separated, dried 
over MgSO4 and concentrated under reduced pressure. The 
residue was purified by column chromatography (7:3 n-
hexane/acetone) to give 8 (411 mg, 41% for three steps) as a 
colourless syrup and 6 and 9 (100 mg, ~10% inseparable mix-
ture, ratio of 6 : 9 ≈ 3 : 1) as a colourless syrup. 
Method II.: A vigorously stirred solution of iodide 7 (440 mg, 
0.876 mmol) in dry pyridine (8.8 mL) AgF (556 mg, 4.379 
mmol, 5.0 equiv.) was added and the reaction mixture was 
stirred in the dark at room temperature for 24 h. After the 
complete disappearance of the starting material the mixture 
was diluted with EtOAc (15 mL), filtered through a pad of 
Celite
®
 and concentrated under reduced pressure. To a stirred 
solution of the crude product (300 mg, 0.801 mmol) in anhy-
drous THF (2.0 mL) a solution of BH3·THF complex in THF 
(1M, 8.0 mL, 8.011 mmol, 10.0 equiv.) was added at 0 °C. 
The reaction mixture was kept at this temperature for 1.5 h. 
Then H2O2 (30%, 2.0 mL) and an aqueous solution of NaOH 
(2M, 4.25 mL) were added at 0 °C and the reaction mixture 
was stirred at room temperature for 50 min. Subsequently, the 
reaction mixture was diluted with EtOAc (100 mL) and 
washed with saturated aqueous solution of NH4Cl (2 x 15 mL), 
H2O (15 mL) and brine (15 mL). The organic layer was sepa-
rated, dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by column chromatography 
(6:4 n-hexane/acetone) to give 8 (204 mg, 66% for three steps) 
as a colourless syrup and 6 and 9 (34 mg, ~11% inseparable 
mixture, ratio of 6 : 9 ≈ 2 : 1) as a colourless syrup and 10 (34 
mg, 11%). 
 Data of the mixture of 6 and 9: Characteristic NMR signals: 
1
H NMR (CDCl3, 400 MHz) δ 5.45 (d, J = 5.1 Hz, 1H, H-1 D-
gluco), 5.12 (d, J = 2.2 Hz, 0.5H, H-1 L-ido-sulfoxide); MS 
(MALDI-TOF): m/z calcd for C21H28NaO5S (6): 415.155 
[M+Na]
+
; found: 415.292; m/z calcd for C21H28NaO6S (9): 
431.151 [M+Na]
+
; found: 431.246. 
Data of 8: [α]D
25
 +52.0 (c 0.55, CHCl3); Rf 0.25 (7:3 n-
hexane/acetone); 
1
H NMR (CDCl3, 400 MHz) δ 7.85-7.47 (m, 
7H, arom), 4.81 (d, J = 12.4 Hz, 1H, NAP-CH2a), 4.80 (d, J = 
1.6 Hz, 1H, H-1), 4.70 (d, J = 12.5 Hz, 1H, NAP-CH2b), 4.02 
(dd, J = 7.9 Hz, J = 11.5 Hz, 1H, H-6a), 3.78 (ddd, J = 1.9 Hz, 
J = 4.3 Hz, J = 6.6 Hz, 1H, H-5), 3.60-3.57 (m, 2H, H-3, H-
6b), 3.51 (s, 3H, OCH3), 3.41 (s, 1H, H-4), 3.30 (s, 4H, H-2, 
OCH3), 2.71 (qd, J = 2.8 Hz, J = 7.4 Hz, 2H, SCH2CH3), 1.99 
(s, 1H, H-6-OH), 1.28 (t, J = 7.4 Hz, 3H, SCH2CH3) ppm; 
13
C 
NMR (CDCl3, 100 MHz) δ 135.4, 133.2, 133.1 (3C, 3 x Cq 
arom), 128.5-126.2 (7C, arom), 83.4 (1C, C-1), 78.5 (1C, C-
2), 77.3 (1C, C-5), 73.3 (1C, C-3), 72.4 (1C, NAP-CH2), 71.4 
(1C, C-4), 62.8 (1C, C-6), 59.2, 58.1 (2C, 2 x OCH3), 25.8 
(1C, SCH2CH3), 15.5 (1C, SCH2CH3) ppm; MS (MALDI-
TOF): m/z calcd for C21H28NaO5S: 415.155 [M+Na]
+
; found: 
415.180; Elemental analysis calcd (%) for C21H28O5S: C, 
64.26; H, 7.19; S, 8.17; found: C, 64.32; H, 7.23; S, 8.22. 
Data of 10: [α]D
25
 +184.0 (c 0.20, CHCl3); Rf 0.64 (6:4 n-
hexane/acetone); 
1
H NMR (CDCl3, 400 MHz) δ 7.85-7.44 (m, 
7H, arom), 5.51 (d, J = 4.0 Hz, 1H, H-1), 5.05 (d, J = 11.3 Hz, 
1H, NAP-CH2a), 4.80 (d, J = 11.3 Hz, 1H, NAP-CH2b), 4.61 
(ddd, J = 1.5 Hz, J = 3.3 Hz, J = 10.3 Hz, J = 95.4 Hz , 1H, H-
6a), 4.61 (dd, J = 2.3 Hz, J = 10.6 Hz, 1H, H-5), 4.19 (dd, J = 
9.5 Hz, J = 29.4 Hz, 1H, H-6b), 3.66 (s, 3H, OCH3), 3.55-3.52 
(m, 3H, H-2, H-3, H-4), 3.51 (s, 3H, OCH3), 2.57 (tdd, J = 5.4 
Hz, J = 7.4 Hz, J = 12.8 Hz, 2H, SCH2CH3), 1.29 (t, J = 7.4 
Hz, 3H, SCH2CH3) ppm; 
13
C NMR (CDCl3, 100 MHz) δ 
135.7, 133.4, 133.2 (3C, 3 x Cq arom), 128.4-126.0 (7C, 
arom), 84.3 (1C, C-1), 82.3 (d, J = 172 Hz, 1C, C-6), 83.0, 
81.8 (2C, C-2, C-3), 76.7 (d, J = 5.9 Hz, 1C, C-4), 75.3 (1C, 
NAP-CH2), 70.2 (d, J = 18.1 Hz, 1C, C-5), 61.3, 58.3 (2C, 2 x 
OCH3), 24.1 (1C, SCH2CH3), 14.8 (1C, SCH2CH3) ppm; MS 
(MALDI-TOF): m/z calcd for C21H27FNaO4S: 417.151 
[M+Na]
+
; found: 417.276; Elemental analysis calcd (%) for 
C21H27FO4S: C, 63.94; H, 6.90; S, 8.13; found: C, 63.99; H, 
6.98; S, 8.21. 
Ethyl 2,3-di-O-methyl-4,6-O-(2-naphthyl)methylene-1-thio-
β-L-idopyranoside (11). To a vigorously stirred solution of 8 
(160 mg, 0.407 mmol) in dry CH2Cl2 (11 mL) DDQ (139 mg, 
0.611 mmol, 1.5 equiv.) and 4 Å MS (115 mg) were added. 
After 50 min the mixture was diluted with CH2Cl2 (100 mL), 
filtered, extracted with a saturated aqueous solution of 
NaHCO3 (2 x 25 mL) and H2O (2 x 25 mL), dried and concen-
trated. The crude product was purified by silica gel chroma-
tography (7:3 n-hexane/acetone) to give 11 (106 mg, 67%) as 
a colourless syrup. [α]D
25
 +55.7 (c 0.21, CHCl3); Rf 0.35 (7:3 
n-hexane/acetone); 
1
H NMR (CDCl3, 400 MHz) δ 7.96-7.44 
(m, 7H, arom), 5.62 (s, 1H, Hac), 4.87 (d, J = 1.3 Hz, 1H, H-1), 
4.36 (d, J = 12.5 Hz, 1H, NAP-CH2a), 4.07 (dd, J = 2.0 Hz, J = 
12.5 Hz, 1H, NAP-CH2b), 3.97 (s, 1H, H-4), 3.70 (t, J = 2.2 
Hz, 1H, H-3), 3.58 (d, J = 1.1 Hz, 1H, H-5), 3.49, 3.47 (2 x s, 
6H, 2 x OCH3), 3.36 (s, 1H, H-2), 2.76 (q, J = 7.4 Hz, 2H, 
SCH2CH3), 1.31 (t, J = 7.4 Hz, 3H, SCH2CH3) ppm; 
13
C NMR 
(CDCl3, 100 MHz) δ 135.8, 133.8, 133.0 (3C, 3 x Cq arom), 
128.4-124.6 (7C, arom), 101.6 (1C, Cac), 82.3 (1C, C-1), 77.2 
(1C, C-2), 75.4 (1C, C-3), 71.7 (1C, C-4), 70.1 (1C, C-6), 68.6 
(1C, C-5), 58.4, 58.2 (2C, 2 x OCH3), 25.6 (1C, SCH2CH3), 
15.1 (1C, SCH2CH3) ppm; MS (MALDI-TOF): m/z calcd for 
C21H26NaO5S: 413.139 [M+Na]
+
; found: 413.256; Elemental 
analysis calcd (%) for C21H26O5S: C, 64.59; H, 6.71; S, 8.21; 
found: C, 64.65; H, 6.78; S, 8.28. 
Methyl [2,3-di-O-methyl-4,6-O-(2-naphthyl)methylene-α-L-
idopyranosyl]-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (13). To a solution of compound 11 (200 
mg, 0.512 mmol) and compound 12
26
 (357 mg, 0.768 mmol, 
1.5 equiv.) in dry CH2Cl2 (6.0 mL) 4 Å molecular sieves (0.25 
g) were added. After stirring at room temperature for 30 min, 
the mixture was cooled to −40 °C and solutions of NIS (173 
mg, 0.768 mmol, 1.5 equiv.) in dry THF (240 µL) and AgOTf 
(32 mg, 0.123 mmol, 0.24 equiv.) in dry toluene (240 µL) 
were added. After stirring at −40 °C to −20 °C for 4 h, TLC 
analysis (6:4 n-hexane/EtOAc) showed complete consumption 
of the donor. The reaction mixture was neutralized with Et3N 
(50 µL), diluted with CH2Cl2 (150 mL), and filtered. The 
filtrate was washed with an aqueous solution of Na2S2O3 
(10%, 25 mL), a saturated aqueous solution of NaHCO3 (2 x 
25 mL), and water (2 x 25 mL), dried, and concentrated. The 
crude product was purified by column chromatography on 
silica gel (6:4 n-hexane/EtOAc) to give compound 13 (294 
mg, 72%) as white crystals. [α]D
25
 +1.1 (c 0.09, CHCl3); Rf 
0.36 (6:4 n-hexane/EtOAc); M.p.: 162-164 °C (EtOAc/n-
hexane); 
1
H NMR (CDCl3, 400 MHz) δ 7.91-7.22 (m, 22H, 
arom), 5.43 (s, 1H, Hac), 5.05 (d, J = 11.2 Hz, 1H, Bn-CH2a), 
4.85 (d, J = 4.9 Hz, 1H, H-1’), 4.78-4.56 (m, 6H, Bn-CH2b, 2 x 
Bn-CH2, H-1), 3.98-3.77 (m, 5H, H-3, H-4, H-4’, H-5’, H-
6’a), 3.70-3.69 (m, 2H, H-6a,b), 3.59 (dd, J = 3.6 Hz, J = 9.5 
Hz, 1H, H-2), 3.54 (s, 1H, H-5), 3.51 (s, 3H, OCH3), 3.46-3.43 
(m, 1H, H-3’), 3.44, 3.38 (2 x s, 6H, 2 x OCH3), 3.20 (dd, J = 
4.9 Hz, J = 9.1 Hz, 1H, H-2’), 3.16 (dd, J = 2.2 Hz, J = 13.2 
Hz, 1H, H-6’b) ppm; 
13
C NMR (CDCl3, 100 MHz) δ 139.2, 
138.1, 137.8, 135.5, 133.6, 132.9 (6C, 6 x Cq arom), 128.5-
124.0 (22C, arom), 100.4, (1C, C-1’), 100.0 (1C, Cac), 98.1 
(1C, C-1), 82.3 (1C, C-3), 80.6 (1C, C-2), 80.3, 80.2 (2C, C-
2’, C-3’), 78.2 (1C, C-4’), 75.7, 73.5, 73.4 (3C, 3 x Bn-CH2), 
73.0 (1C, C-4), 70.6 (1C, C-5), 68.7 (1C, C-6’), 68.5 (1C, C-
6), 62.0 (1C, C-5’), 59.8, 58.6 (2C, 2 x OCH3), 55.2 (1C, C-1-
OCH3) ppm; MS (MALDI-TOF): m/z calcd for C47H52NaO11: 
815.340 [M+Na]
+
; found: 815.417; Elemental analysis calcd 
(%) for C47H52O11: C, 71.19; H, 6.61; found: C, 71.24; H, 6.65. 
Methyl [2,3-di-O-methyl-6-O-(2-naphthyl)methyl-α-L-
idopyranosyl]-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (14) and methyl (2,3-di-O-methyl-α-L-
idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (15). Method I.: To a solution of compound 
13 (250 mg, 0.315 mmol) in anhydrous CH2Cl2 (3.2 mL) at 0 
°C Et3SiH (604 µL, 3.784 mmol, 12.0 equiv.) and BF3∙Et2O 
(80 µL, 0.631 mmol, 2.0 equiv.) were added. The reaction 
mixture was stirred for 2 h at 0 °C. Than the mixture was 
diluted with CH2Cl2 (100 mL), washed with saturated aqueous 
solution of NaHCO3 (2 x 20 mL), dried over MgSO4 and con-
centrated. The crude product was purified by column chroma-
tography on silica gel (1:1 n-hexane/EtOAc) to give com-
pound 14 (52 mg, 20%) as a colourless syrup and compound 
15 (105 mg, 42%) as a colourless syrup. 
Method II.: To a solution of compound 13 (126 mg, 0.159 
mmol) in anhydrous THF (500 µL) 4 Å MS (121 mg) and 
Me3N∙BH3 (70 mg, 0.953 mmol, 6.0 equiv.) were added and 
stirred for 30 min at room temperature. After 30 min AlCl3 
 (127 mg, 0.953 mmol, 6.0 equiv.) was added and the reaction 
mixture was stirred at room temperature for 30 min. The mix-
ture was diluted with CH2Cl2 (100 mL), washed with water (2 
x 20 mL), dried over MgSO4 and concentrated. The crude 
product was purified by column chromatography on silica gel 
(1:1 n-hexane/EtOAc) to give compound 14 (101 mg, 80%) as 
a colourless syrup. 
Data of 14: [α]D
25
 +3.3 (c 0.12, CHCl3); Rf 0.40 (1:1 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 7.80-7.20 (m, 
22H, arom), 5.08 (s, 1H, H-1’), 4.95-4.43 (m, 9H, NAP-CH2, 3 
x Bn-CH2, H-1), 4.39 (td, J = 1.3 Hz, J = 5.7 Hz, 1H, H-5’), 
3.94-3.86 (m, 2H), 3.79-3.57 (m, 5H), 3.52-3.46 (m, 3H), 
3.40, 3.34, 3.27 (3 x s, 9H, 3 x OCH3), 3.20 (s, 1H), 3.14 (d, J 
= 9.3 Hz, 1H, C-4-OH) ppm; 
13
C NMR (CDCl3, 100 MHz) δ 
139.2, 138.2, 138.0, 135.9, 133.3, 132.9 (6C, 6 x Cq arom), 
128.4-125.7 (22C, arom), 98.1 (2C, C-1, C-1’), 80.4, 80.3, 
77.5, 77.4, 74.6, 70.1, 66.9, 66.8 (8C, skeleton carbons), 75.4, 
73.5, 73.3 (4C, NAP-CH2, 3 x Bn-CH2), 69.8, 68.9 (2C, C-6, 
C-6’), 58.5, 58.3 (2C, 2 x OCH3), 55.2 (1C, C-1-OCH3) ppm; 
MS (MALDI-TOF): m/z calcd for C47H54NaO11: 817.356 
[M+Na]
+
; found: 817.381; Elemental analysis calcd (%) for 
C47H54O11: C, 71.01; H, 6.85; found: C, 71.07; H, 6.91. 
Data of 15: [α]D
25
 −5.5 (c 0.20, CHCl3); Rf 0.13 (1:1 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 400 MHz) δ 7.27-7.18 (m, 
15H, arom), 4.96 (d, J = 10.5 Hz, 1H, Bn-CH2a), 4.89 (s, 1H, 
H-1’), 4.72-4.45 (m, 6H, Bn-CH2b, 2 x Bn-CH2, H-1), 4.08-
4.06 (m, 1H, H-5’), 3.84-3.78 (m, 2H, H-3, H-3’), 3.72-3.70 
(m, 1H, H-4), 3.56 (s, 2H, H-6a,b), 3.51 (dd, J = 3.3 Hz, J = 
8.8 Hz, 1H, H-2), 3.45-3.40 (m, 1H, H-5), 3.37 (s, 3H, OCH3), 
3.35-3.31 (m, 1H, H-4’), 3.29, 3.17 (2 x s, 6H, 2 x OCH3), 
3.28-3.12 (m, 2H, H-6’a,b), 3.07-3.05 (m, 1H, H-2’), 1.83 (s, 
1H, C-6’-OH), 1.24 (s, 1H, C-4’-OH) ppm; 
13
C NMR (CDCl3, 
100 MHz) δ 138.5, 138.0, 137.7 (3C, 3 x Cq arom), 128.5-
127.7 (15C, arom), 98.0, (1C, C-1), 97.0 (1C, C-1), 80.3 (1C, 
C-2), 80.1 (1C, C-3), 76.9, 76.8 (2C, C-2’, C-4’), 75.8, 73.6 
(2C, 2 x Bn-CH2), 73.5 (1C, C-3’), 73.4 (1C, Bn-CH2), 70.2 
(1C, C-4), 68.9 (1C, C-6), 67.1, 67.0 (2C, C-5, C-5’), 63.0 
(1C, C-6’), 58.4, 58.2 (2C, 2 x OCH3), 55.2 (1C, C-1-OCH3) 
ppm; MS (MALDI-TOF): m/z calcd for C36H46NaO11: 667.293 
[M+Na]
+
; found: 667.344; Elemental analysis calcd (%) for 
C36H46O11: C, 66.04; H, 7.08; found: C, 66.11; H, 7.16. 
Methyl (6-O-tert-butyldiphenylsilyl-2,3-di-O-methyl-α-L-
idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (16). To a solution of 15 (103 mg, 0.157 
mmol) in dry pyridine (540 µL), tert-butyldiphenylsilyl chlo-
ride (81 µL, 0.314 mmol, 2 equiv.) was added. The mixture 
was stirred for 24 h at room temperature. After the complete 
disappearance of the starting material, the mixture was con-
centrated. The residue was dissolved in EtOAc (75 mL), 
washed with 1 M aqueous solution of HCl (2 x 10 mL), water 
(10 mL), saturated aqueous solution of NaHCO3 (2 x 10 mL), 
and water (2 x 10 mL), dried, and concentrated. The crude 
product was purified by column chromatography on silica gel 
(7:3 n-hexane/acetone) to give compound 16 (111 mg, 79%) 
as a colourless syrup. [α]D
25
 +5.4 (c 0.13, CHCl3); Rf 0.41 (7:3 
n-hexane/acetone); 
1
H NMR (CDCl3, 400 MHz) δ 7.69-7.15 
(m, 25H, arom), 5.08 (s, 1H, H-1’), 4.88-4.49 (m, 7H, 3 x Bn-
CH2, H-1), 4.26 (t, J = 5.1 Hz, 1H, H-5’), 3.93-3.84 (m, 2H), 
3.83-3.75 (m, 4H), 3.69-3.61 (m, 2H), 3.51-3.47 (m, 2H), 
3.41, 3.36, 3.24 (3 x s, 9H, 3 x OCH3), 3.18 (s, 1H), 1.26 (s, 
1H, C-4’-OH), 1.02 (s, 9H, 3 x t-Bu-CH3) ppm; 
13
C NMR 
(CDCl3, 100 MHz) δ 139.0, 138.3, 138.1, 133.4, 133.3 (5C, 5 
x Cq arom), 129.6-127.3 (25C, arom), 98.4, 98.3 (2C, C-1, C-
1’), 80.8, 80.2, 77.8, 77.6, 74.4, 70.0, 68.1, 66.7 (8C, skeleton 
carbons), 75.6, 73.6 (2C, 2 x Bn-CH2), 69.0 (1C, C-6), 63.5 
(1C, C-6’), 58.4, 58.3 (2C, 2 x OCH3), 55.2 (1C, C-1-OCH3), 
26.9 (3C, 3 x t-Bu-CH3), 19.2 (1C, Cq t-Bu) ppm; MS 
(MALDI-TOF): m/z calcd for C52H64NaO11Si: 915.411 
[M+Na]
+
; found: 915.550; Elemental analysis calcd (%) for 
C52H64O11Si: C, 69.93; H, 7.22; found: C, 70.01; H, 7.31. 
Methyl (2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
glucopyranosyl)-(1→4)-(6-O-tert-butyldiphenylsilyl-2,3-di-
O-methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (18). To a solution of compound 16 (54 mg, 
0.060 mmol) and compound 17
31
 (52 mg, 0.096 mmol, 1.6 
equiv.) in dry CH2Cl2 (708 µL) 4 Å molecular sieves (50 mg) 
were added. After stirring at room temperature for 30 min, the 
mixture was cooled to −40 °C and solutions of NIS (33 mg, 
0.145 mmol, 1.5 equiv.) in dry THF (45 µL) and AgOTf (6.0 
mg, 0.023 mmol, 0.24 equiv.) in dry toluene (45 µL) were 
added. After stirring at −40 °C to −20 °C for 4 h, TLC analysis 
(7:3 n-hexane/EtOAc) showed complete consumption of the 
donor. The reaction mixture was neutralized with Et3N (25 
µL), diluted with CH2Cl2 (75 mL), and filtered. The filtrate 
was washed with an aqueous solution of Na2S2O3 (10%, 10 
mL), a saturated aqueous solution of NaHCO3 (2 x 10 mL), 
and water (2 x 10 mL), dried, and concentrated. The crude 
product was purified by column chromatography on silica gel 
(7:3 n-hexane/EtOAc) to give compound 18 (70 mg, 88%) as a 
colourless syrup. [α]D
25
 −1.8 (c 0.11, CHCl3); Rf 0.30 (7:3 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 7.74-7.19 (m, 
40H, arom), 5.50 (s, 1H, Hac), 5.28 (d, J = 3.9 Hz, 1H, H-1”), 
5.01 (d, J = 7.2 Hz, 1H, H-1’), 4.99-4.62 (m, 8H, 4 x Bn-CH2), 
4.62 (d, J = 3.6 Hz, 1H, H-1), 4.49 (q, J = 12.2 Hz, 2H, Bn-
CH2), 4.01 (dd, J = 4.5 Hz, J = 10.1 Hz, 1H, H-6”a), 3.93-3.84 
(m, 7H, H-3, H-3’, H-3”, H-4’, H-5, H-6a, H-6’a), 3.77-3.75 
(m, 2H, H-5’, H-6’b), 3.65-3.56 (m, 5H, H-2”, H-4, H-4”, H-
6b, H-6”b), 3.55-3.52 (m, 1H, H-5”), 3.51 (s, 3H, C-3’-OCH3), 
3.49-3.48 (m, 1H, H-2), 3.46 (s, 3H, C-2’-OCH3), 3.42 (s, 3H, 
C-1-OCH3), 3.00 (t, J = 7.7 Hz, 1H, H-2’), 1.03 (s, 9H, 3 x t-
Bu-CH3) ppm; 
13
C NMR (CDCl3, 125 MHz) δ 139.5, 139.0, 
138.6, 138.5, 138.3, 137.5, 132.9, 132.7 (8C, 8 x Cq arom), 
129.9-126.2 (40C, arom), 101.2 (1C, Cac), 101.0 (1C, C-1’), 
99.4 (1C, C-1”), 98.1 (1C, C-1), 85.5 (1C, C-2’), 82.5 (1C, C-
3’), 82.4 (1C, C-4”), 80.6 (1C, C-3), 79.2 (1C, C-2), 79.1 (1C, 
C-2”), 78.9 (1C, C-4), 78.7 (1C, C-3”), 75.9 (1C, C-4’), 75.6, 
75.2 (2C, 2 x Bn-CH2), 73.8 (1C, C-5’), 73.7, 73.4 (3C, 3 x 
Bn-CH2), 70.8 (1C, C-5), 69.4 (1C, C-6), 68.8 (1C, C-6”), 63.2 
(1C, C-5”), 62.8 (1C, C-6’), 60.6, 60.5 (2C, 2 x OCH3), 55.3 
(1C, C-1-OCH3), 27.1 (3C, 3 x t-Bu-CH3), 19.1 (1C, Cq t-Bu) 
ppm; MS (MALDI-TOF): m/z calcd for 
C79H90NaO16Si:1345.589 [M+Na]
+
; found: 1345.662; Ele-
mental analysis calcd (%) for C79H90O16Si: C, 71.69; H, 6.85; 
found: C, 71.75; H, 6.91. 
Methyl (2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(6-
O-tert-butyldiphenylsilyl-2,3-di-O-methyl-α-L-
idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (19a) and methyl (2,3,4-tri-O-benzyl-α-D-
glucopyranosyl)-(1→4)-(6-O-tert-butyldiphenylsilyl-2,3-di-
O-methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (19b). To a solution of 18 (63 mg, 0.048 
mmol) in dry THF (144 µL) 4 Å MS (36 mg) and Me3N·BH3 
(21 mg, 0.286 mmol, 6 equiv.) were added and the reaction 
mixture was stirred for 30 min at room temperature. After 30 
min AlCl3 (38 mg, 0.286 mmol, 6 equiv.) was added and the 
 mixture was stirred at room temperature for 2 h. After 2.5 h 
the reaction mixture was diluted with CH2Cl2 (5.0 mL), and 
washed with H2O (2 x 5 mL). The organic layer was dried 
over MgSO4 and concentrated. The crude product was purified 
by silica gel chromatography (7:3 n-hexane/acetone) to give 
19a (40 mg, 65%) as a colourless syrup and 19b (13 mg, 21%) 
as a colourless syrup. 
Data of 19a: [α]D
25
 +13.0 (c 0.13, CHCl3); Rf 0.36 (7:3 n-
hexane/acetone); 
1
H NMR (CDCl3, 500 MHz) δ 7.72-7.12 (m, 
40H, arom), 5.27 (d, J = 3.5 Hz, 1H, H-1”), 4.99 (d, J = 7.2 
Hz, 1H, H-1’), 4.97-4.62 (m, 8H, 4 x Bn-CH2), 4.60 (d, J = 3.6 
Hz, 1H, H-1), 4.52-4.40 (m, 4H, 2 x Bn-CH2), 3.93 (dd, J = 
4.7 Hz, J = 11.3 Hz, 1H, H-6’a), 3.89-3.83 (m, 6H, H-3, H-3’, 
H-4, H-4’, H-5’, H-6a), 3.81-3.79 (m, 1H, H-6’b), 3.67-3.56 
(m, 4H, H-3”, H-4”, H-5, H-6b), 3.54-3.49 (m, 2H, H-2”, H-
6”a), 3.50 (s, 3H, C-3’-OCH3), 3.47-3.46 (m, 1H, H-2), 3.45 
(s, 3H, C-2’-OCH3), 3.41 (s, 3H, C-1-OCH3), 3.42-3.35 (m, 
2H, H-5”, H-6”b), 3.01 (t, J = 7.2 Hz, 1H, H-2’), 2.24 (d, J = 
2.5 Hz, 1H, C-4”-OH), 1.04 (s, 9H, 3 x t-Bu-CH3) ppm; 
13
C 
NMR (CDCl3, 125 MHz) δ 139.6, 139.0, 138.6, 138.5, 138.3, 
138.0, 133.2, 132.9 (8C, 8 x Cq arom), 129.9-127.2 (40C, 
arom), 100.8 (1C, C-1’), 98.6 (1C, C-1”), 98.2 (1C, C-1), 85.1 
(1C, C-2’), 82.1 (1C, C-3’), 81.4 (1C, C-3”), 80.6 (1C, C-3), 
79.2 (1C, C-2), 79.1 (1C, C-2”), 78.8 (1C, C-4”), 76.0 (1C, C-
4’), 75.6, 75.3, 73.8, 73.7 (4C, 4 x Bn-CH2), 73.6 (1C, C-4), 
73.4, 72.5 (2C, 2 x Bn-CH2), 70.9, 70.8, 70.7 (3C, C-5, C-5’, 
C-5”), 69.3 (1C, C-6), 69.1 (1C, C-6”), 62.8 (1C, C-6’), 60.5, 
60.4 (2C, 2 x OCH3), 55.3 (1C, C-1-OCH3), 27.1 (3C, 3 x t-
Bu-CH3), 19.3 (1C, Cq t-Bu) ppm; MS (MALDI-TOF): m/z 
calcd for C79H92NaO16Si: 1347.605 [M+Na]
+
; found: 
1347.695; Elemental analysis calcd (%) for C79H92O16Si: C, 
71.58; H, 7.00; found: C, 71.64; H, 7.07. 
Data of 19b: [α]D
25
 +17.2 (c 0.97, CHCl3); Rf 0.31 (7:3 n-
hexane/acetone); 
1
H NMR (CDCl3, 500 MHz) δ 7.70-7.18 (m, 
40H, arom), 5.24 (d, J = 3.6 Hz, 1H, H-1”), 4.99 (d, J = 10.6 
Hz, 1H, Bn-CH2a), 4.96 (d, J = 7.0 Hz, 1H, H-1’), 4.91-4.61 
(m, 9H, Bn-CH2b, 4 x Bn-CH2), 4.60 (d, J = 3.0 Hz, 1H, H-1), 
4.47 (q, J = 12.2 Hz, 2H, Bn-CH2), 3.91 (dd, J = 4.9 Hz, J = 
11.3 Hz, 1H, H-6’a), 3.88-3.76 (m, 8H, H-3, H-3’, H-3”, H-4’, 
H-5, H-5’, H-6a, H-6’b), 3.65 (t, J = 9.4 Hz, 1H, H-4), 3.58 
(dd, J = 7.0 Hz, J = 10.8 Hz, 1H, H-6b), 3.53-3.46 (m, 5H, H-
2, H-2”, H-4”, H-6”a,b), 3.50 (s, 3H, C-3’-OCH3), 3.46 (s, 3H, 
C-2’-OCH3), 3.41 (s, 3H, C-1-OCH3), 3.38-3.36 (m, 1H, H-
5”), 3.00 (t, J = 7.2 Hz, 1H, H-2’), 1.48-1-45 (m, 1H, C-6”-
OH), 1.04 (s, 9H, 3 x t-Bu-CH3) ppm; 
13
C NMR (CDCl3, 125 
MHz) δ 139.6, 138.5, 138.4, 133.2, 132.8, 131.2 (8C, 8 x Cq 
arom), 128.5-127.2 (40C, arom), 100.7 (1C, C-1’), 98.6 (1C, 
C-1”), 98.2 (1C, C-1), 85.2 (1C, C-2’), 82.3 (1C, C-3’), 81.8 
(1C, C-3”), 80.6 (1C, C-3), 79.7 (1C, C-2”), 79.2 (1C, C-2), 
78.8 (1C, C-4), 77.5 (1C, C-4”), 76.2 (1C, C-4’), 75.6, 75.2 
(4C, 4 x Bn-CH2), 74.2 (1C, C-5’), 73.4, 72.8 (2C, 2 x Bn-
CH2), 71.8 (1C, C-5”), 70.8 (1C, C-5), 69.3 (1C, C-6), 62.6 
(1C, C-6’), 61.8 (1C, C-6”), 60.5, 60.4 (2C, 2 x OCH3), 55.3 
(1C, C-1-OCH3), 27.1 (3C, 3 x t-Bu-CH3), 19.2 (1C, Cq t-Bu) 
ppm; MS (MALDI-TOF): m/z calcd for C79H92NaO16Si: 
1347.605 [M+Na]
+
; found: 1347.877; Elemental analysis calcd 
(%) for C79H92O16Si: C, 71.58; H, 7.00; found: C, 71.68; H, 
7.08. 
Methyl (2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
glucopyranosyl)-(1→4)-(2,3-di-O-methyl-6-O-(2-
naphthyl)methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (20). To a solution of compound 
15 (90 mg, 0.113 mmol) and compound 17
31
 (98 mg, 0.181 
mmol, 1.6 equiv.) in dry CH2Cl2 (1320 µL) 4 Å molecular 
sieves (80 mg) were added. After stirring at room temperature 
for 30 min, the mixture was cooled to −40 °C and solutions of 
NIS (61 mg, 0.272 mmol, 1.5 equiv.) in dry THF (84 µL) and 
AgOTf (11 mg, 0.043 mmol, 0.24 equiv.) in dry toluene (84 
µL) were added. After stirring at −40 °C to −20 °C for 4 h, 
TLC analysis (7:3 n-hexane/EtOAc) showed complete con-
sumption of the donor. The reaction mixture was neutralized 
with Et3N (200 µL), diluted with CH2Cl2 (100 mL), and fil-
tered. The filtrate was washed with an aqueous solution of 
Na2S2O3 (10%, 20 mL), a saturated aqueous solution of 
NaHCO3 (2 x 20 mL), and water (2 x 20 mL), dried, and con-
centrated. The crude product was purified by column chroma-
tography on silica gel (65:35 n-hexane/EtOAc) to give com-
pound 20 (111 mg, 80%) as a colourless syrup. [α]D
25
 +11.0 (c 
0.10, CHCl3); Rf 0.50 (6:4 n-hexane/EtOAc); 
1
H NMR 
(CDCl3, 500 MHz) δ 7.72-7.19 (m, 37H, arom), 5.52 (s, 1H, 
Hac), 5.25 (d, J = 3.8 Hz, 1H, H-1”), 4.98 (d, J = 6.9 Hz, 1H, 
H-1’), 4.98-4.60 (m, 8H, 4 x Bn-CH2), 4.58 (d, J = 4.0 Hz, 1H, 
H-1), 4.48-4.38 (m, 4H, NAP-CH2, Bn-CH2), 4.15 (dd, J = 4.7 
Hz, J = 10.1 Hz, 1H, H-6”a), 4.04 (dd, J = 4.6 H, J = 9.5 Hz, 
1H, H-5’), 3.93-3.88 (m, 4H, H-3, H-3”, H-4, H-4’), 3.79-3.74 
(m, 5H, H-3’, H-5, H-5”, H-6a, H-6’a), 3.71-3.64 (m, 3H, H-
6b, H-6’b, H-6”b), 3.60 (t, J = 9.4 Hz, 1H, H-4”), 3.58 (dd, J = 
3.8 Hz, J = 9.4 Hz, 1H, H-2”), 3.52 (s, 3H, C-3’-OCH3), 3.50-
3.47 (m, 1H, H-2), 3.49 (s, 3H, C-2’-OCH3), 3.36 (s, 3H, C-1-
OCH3), 3.05 (t, J = 7.4 Hz, 1H, H-2’) ppm; 
13
C NMR (CDCl3, 
125 MHz) δ 139.4, 138.8, 138.5, 138.3, 137.5, 135.8, 133.3, 
132.8 (9C, 9 x Cq arom), 129.9-125.6 (37C, arom), 101.2 (1C, 
Cac), 100.0 (1C, C-1’), 99.1 (1C, C-1”), 98.4 (1C, C-1), 84.8 
(1C, C-2’), 82.5 (1C, C-3’), 82.3 (1C, C-4”), 80.2 (1C, C-3), 
79.4 (1C, C-2), 79.0 (1C, C-2”), 78.3 (1C, C-4’), 76.6 (1C, C-
4), 76.3 (1C, C-3”), 75.3, 75.0, 73.6, 73.2 (6C, NAP-CH2, 5 x 
Bn-CH2), 72.2 (1C, C-5’), 70.4 (1C, C-5), 69.1 (1C, C-6’), 
68.9 (1C, C-6”), 68.3 (1C, C-6), 63.3 (1C, C-5”), 60.4, 60.3 
(2C, 2 x OCH3), 55.3 (1C, C-1-OCH3) ppm; MS (MALDI-
TOF): m/z calcd for C74H80NaO16: 1247.534 [M+Na]
+
; found: 
1247.618; Elemental analysis calcd (%) for C74H80O16: C, 
72.53; H, 6.58; found: C, 72.59; H, 6.64. 
Methyl (2,3,6-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-
(2,3-di-O-methyl-6-O-(2-naphthyl)methyl-α-L-
idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (21a) and methyl (2,3,4-tri-O-benzyl-α-D-
glucopyranosyl)-(1→4)-(2,3-di-O-methyl-6-O-(2-
naphthyl)methyl-α-L-idopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (21b). To a solution of 20 (95 
mg, 0.077 mmol) in dry THF (235 µL) 4 Å MS (60 mg) and 
Me3N·BH3 (34 mg, 0.465 mmol, 6 equiv.) were added and the 
reaction mixture was stirred for 30 min at room temperature. 
After 30 min AlCl3 (62 mg, 0.465 mmol, 6 equiv.) was added 
and the mixture was stirred at room temperature for 2 h. After 
2 h the reaction mixture was diluted with CH2Cl2 (50 mL), and 
washed with H2O (2 x 15 mL). The organic layer was dried 
over MgSO4 and concentrated. The crude product was purified 
by silica gel chromatography (6:4 n-hexane/EtOAc) to give 
21a (66 mg, 70%) as a colourless syrup and 21b (18 mg, 19%) 
as a colourless syrup. 
Data of 21a: [α]D
25
 +26.7 (c 0.12, CHCl3); Rf 0.66 (1:1 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 7.74-7.16 (m, 
37H, arom), 5.27 (d, J = 3.5 Hz, 1H, H-1”), 4.98 (d, J = 7.4 
Hz, 1H, H-1’), 4.96-4.60 (m, 8H, 4 x Bn-CH2), 4.58 (d, J = 4.3 
Hz, 1H, H-1), 4.49-4.36 (m, 6H, NAP-CH2, 2 x Bn-CH2), 4.10 
 (dd, J = 4.8 Hz, J = 9.8 Hz, 1H, H-5’), 3.94-3.86 (m, 3H, H-3, 
H-4, H-4’), 3.80 (dd, J = 3.7 Hz, J = 10.7 Hz, 1H, H-6a), 3.77-
3.73 (m, 3H, H-3’, H-5, H-6’a), 3.69-3.60 (m, 5H, H-3”, H-4”, 
H-5”, H-6b, H-6’b), 3.55-3.50 (m, 2H, H-2”, H-6”a), 3.51 (s, 
3H, C-3’-OCH3), 3.49-3.44 (m, 2H, H-2, H-6”b), 3.47 (s, 3H, 
C-2’-OCH3), 3.36 (s, 3H, C-1-OCH3), 3.06 (t, J = 7.3 Hz, 1H, 
H-2’), 2.23 (s, 1H, C-4”-OH) ppm; 
13
C NMR (CDCl3, 125 
MHz) δ 139.4, 138.8, 138.6, 138.4, 138.0, 135.9, 133.4, 132.9 
(9C, 9 x Cq arom), 128.6-125.8 (37C, arom), 100.0 (1C, C-1’), 
98.4 (1C, C-1), 98.0 (1C, C-1”), 84.5 (1C, C-2’), 82.2 (1C, C-
3’), 80.9 (1C, C-3”), 80.3 (1C, C-3), 79.5 (1C, C-2), 79.3 (1C, 
C-2”), 76.6 (1C, C-4), 76.0 (1C, C-4’), 75.5, 75.2, 73.7, 73.6, 
73.3, 72.4 (7C, NAP-CH2, 6 x Bn-CH2), 71.9 (1C, C-5’), 70.9, 
70.8 (2C, C-4”, C-5”), 70.5 (1C, C-5), 69.4 (1C, C-6’), 69.2 
(1C, C-6”), 68.4 (1C, C-6), 60.3, 60.2 (2C, 2 x OCH3), 55.4 
(1C, C-1-OCH3) ppm; MS (ESI-TOF): m/z calcd for 
C74H82NaO16: 1249.5495 [M+Na]
+
; found: 1249.5487. 
Data of 21b: [α]D
25
 +31.8 (c 2.70, CHCl3); Rf 0.46 (1:1 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 7.72-7.19 (m, 
37H, arom), 5.24 (d, J = 3.6 Hz, 1H, H-1”), 4.97 (d, J = 10.8 
Hz, 1H, Bn-CH2a), 4.98 (d, J = 6.9 Hz, 1H, H-1’), 4.89-4.69 
(m, 7H, Bn-CH2b, 3 x Bn-CH2), 4.60-4.58 (m, 2H, Bn-CH2), 
4.57 (d, J = 4.6 Hz, 1H, H-1), 4.49-4.36 (m, 4H, NAP-CH2, 
Bn-CH2), 4.06 (dd, J = 4.6 Hz, J = 9.6 Hz, 1H, H-5’), 3.93-
3.84 (m, 4H, H-3, H-3”, H-4, H-4’), 3.79 (dd, J = 3.7 Hz, J = 
10.7 Hz, 1H, H-6a), 3.76-3.72 (m, 3H, H-3’, H-5, H-6’a), 
3.69-3.66 (m, 2H, H-6b, H-6’b), 3.60-3.55 (m, 3H, H-5”, H-
6”a,b), 3.52-3.46 (m, 3H, H-2, H-2”, H-4”), 3.51 (s, 3H, C-3’-
OCH3), 3.48 (s, 3H, C-2’-OCH3), 3.37 (s, 3H, C-1-OCH3), 
3.05 (t, J = 7.3 Hz, 1H, H-2’), 1.70 (s, 1H, C-6”-OH) ppm; 
13
C 
NMR (CDCl3, 125 MHz) δ 139.4, 138.8, 138.6, 138.4, 138.3, 
135.9, 133.4, 132.9 (9C, 9 x Cq arom), 128.6-125.7 (37C, 
arom), 100.1 (1C, C-1’), 98.5 (1C, C-1), 98.0 (1C, C-1”), 84.7 
(1C, C-2’), 82.5 (1C, C-3’), 81.7 (1C, C-3”), 80.3 (1C, C-3), 
79.9 (1C, C-2”), 79.5 (1C, C-2), 77.3 (1C, C-4”), 76.7 (1C, C-
4), 76.1 (1C, C-4’), 75.5, 75.4, 75.2, 73.7, 73.3, 72.8 (7C, 
NAP-CH2, 6 x Bn-CH2), 72.0 (1C, C-5’), 71.7 (1C, C-5”), 
70.5 (1C, C-5), 69.2 (1C, C-6’), 68.4 (1C, C-6), 61.7 (1C, C-
6”), 60.4 (2C, 2 x OCH3), 55.4 (1C, C-1-OCH3) ppm; MS 
(MALDI-TOF): m/z calcd for C74H82NaO16: 1249.550 
[M+Na]
+
; found: 1249.599; Elemental analysis calcd (%) for 
C74H82O16: C, 72.41; H, 6.73; found: C, 72.49; H, 6.81. 
Methyl (6-O-benzyl-2,3,4-tri-O-methyl-α-D-
glucopyranosyl)-(1→4)-[2,3-di-O-acetyl-6-O-(2-
naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-(2,3,6-tri-O-
benzyl-α-D-glucopyranosyl)-(1→4)-(6-O-tert-
butyldiphenylsilyl-2,3-di-O-methyl-α-L-idopyranosyl)-
(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (23) and 
methyl (6-O-benzyl-2,3,4-tri-O-methyl-α-D-
glucopyranosyl)-(1→4)-[2,3-di-O-acetyl-6-O-(2-
naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (24). To a solution of 
trisaccharide acceptor 19a (32 mg, 0.024 mmol) and disaccha-
ride donor 22
32
 (28.6 mg, 0.036 mmol, 1.5 equiv.) in dry 
CH2Cl2 (1.2 mL) 4 Å MS (150 mg) were added and the reac-
tion mixture was stirred at room temperature. After 30 min the 
stirred mixture was cooled to −20 °C under argon. After at this 
temperature, NIS (12 mg, 0.054 mmol, 1.5 equiv. to the donor) 
was dissolved in dry THF (30 µL) and AgOTf (2 mg, 0.009 
mmol, 0.24 equiv. to the donor) dissolved in dry toluene (30 
µL) were added. The temperature was allowed to warm up to 
+5 °C and the reaction mixture was stirred for 4 h. After 4 h 
the reaction mixture was quenched with Et3N (150 µL), dilut-
ed with CH2Cl2 (25 mL), filtered and the mixture was washed 
with saturated aqueous solution of Na2S2O3 (2 x 5 mL), satu-
rated aqueous solution of NaHCO3 (5 mL) and with H2O (2 x 
5 mL) until neutral pH. The organic layer was dried on MgSO4 
and concentrated. The crude product was purified by silica gel 
chromatography (6:4 n-hexane/EtOAc to 1:1 n-
hexane/EtOAc) to give 23 (5 mg, 11%) as a colourless syrup 
and 24 (22 mg, 46%) as a colourless syrup. 
Data of 23: [α]D
25
 +27.0 (c 0.10, CHCl3); Rf 0.48 (1:1 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 7.80-7.10 (m, 
52H, arom), 5.27 (d, J = 3.8 Hz, 1H, H-1”), 5.12-4.25 (m, 
22H, 7 x Bn-CH2, NAP-CH2, 4 x H-1, H-2-E, H-3-E), 3.96-
2.98 (m, 46H, 6 x OCH3, 28 skeleton hydrogen), 2.02, 1.95 (2 
x s, 6H, 2 x Ac-CH3), 1.03 (s, 9H, t-Bu-CH3) ppm; 
13
C NMR 
(CDCl3, 125 MHz) δ 148.7, 147.5, 144.8, 143.8, 143.5, 139.5, 
138.3, 137.6, 133.3, 133.2, 132.9, 132.8 (12C, 12 x Cq arom), 
135.7-125.6 (52C, arom), 101.1, 100.0, 98.9, 98.2, 98.0 (5C, 5 
x C-1), 85.0, 83.4, 82.0, 80.6, 80.4, 79.4, 79.2, 76.8, 75.6, 
75.3, 75.2, 73.0, 71.4, 71.1, 69.0, 68.5, 67.7 (20C, skeleton 
carbons), 75.1, 73.5, 73.1 (9C, 7 x Bn-CH2, 2 x NAP-CH2), 
70.9, 70.8, 70.7 (3C, C-5, C-5’, C-5”), 67.7, 68.5, 68.7, 69.0 
(4C, 4 x C-6), 63.2 (1C, C-6-G), 60.9, 60.5, 59.4 (5C, 5 x 
OCH3), 55.4 (1C, C-1-OCH3), 21.2, 20.9 (2C, 2 x Ac-CH3), 
27.1 (3C, 3 x t-Bu-CH3), 19.2 (1C, Cq t-Bu) ppm; MS 
(MALDI-TOF): m/z calcd for C116H136NaO28Si: 2027.888 
[M+Na]
+
; found: 2027.809. 
Data of 24: [α]D
25
 +25.8 (c 0.12, CHCl3); Rf 0.35 (1:1 n-
hexane/EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 7.81-7.13 (m, 
27H, arom), 5.11 (t, J = 9.1 Hz, 1H, H-3’), 5.07 (d, J = 3.5 Hz, 
1H, H-1”), 5.02 (d, J = 11.6 Hz, 1H, Bn-CH2a), 4.85 (dd, J = 
9.4 Hz J = 8.2 Hz, 1H, H-2’), 4.77-4.58 (m, 5H, Bn-CH2b, 2 x 
Bn-CH2), 4.56-4.52 (m, 2H, H-1, H-1’), 4.48-4.27 (m, 4H, 
NAP-CH2, Bn-CH2), 3.92 (t, J = 9.2 Hz, 1H, H-4’), 3.90-3.85 
(m, 2H, H-3, H-4), 3.75 (dd, J = 10.7 Hz, J = 3.2 Hz, 1H, H-
6a), 3.69-3.60 (m, 5H, H-5, H-5”, H-6b, H-6’a,b), 3.58 (s, 3H, 
C-3’-OCH3), 3.44 (dd, J = 10.1 Hz, J = 3.3 Hz, 1H, H-6”a), 
3.42-3.37 (m, 3H, H-2, H-3”, H-6”b), 3.41, 3.40 (2 x s, 6H, C-
4”-OCH3, C-2”-OCH3), 3.34 (s, 3H, C-1-OCH3), 3.23-3.21 (m, 
1H, H-5’), 3.17 (t, J = 9.5 Hz, 1H, H-4”), 3.05 (dd, J = 9.8 Hz, 
J = 3.5 Hz, 1H, H-2”), 2.01, 1.94 (2 x s, 6H, 2 Ac-CH3) ppm; 
13
C NMR (CDCl3, 125 MHz) δ 170.1, 169.8 (2C, 2 x Cq Ac), 
139.6, 138.4, 138.2, 137.8, 136.2, 133.4, 133.0 (7C, 7 x Cq 
arom), 128.8-125.8 (27C, arom), 100.0 (1C, C-1’), 98.5 (1C, 
C-1), 97.9 (1C, C-1”), 83.3 (1C, C-3”), 81.9 (1C, C-2”), 80.3 
(1C, C-3), 79.4 (1C, C-4”), 79.3 (1C, C-2), 77.1 (1C, C-4), 
75.3 (1C, C-3’), 75.2 (1C, C-5’), 75.0 (1C, C-4’), 74.0, 73.8, 
73.4 (5C, 4 x Bn-CH2, NAP-CH2), 73.0 (1C, C-2’), 71.3 (1C, 
C-5”), 70.0 (1C, C-5), 68.8 (1C, C-6’), 68.5 (1C, C-6”), 67.9 
(1C, C-6), 60.8 (1C, C-3”-OCH3), 60.5 (1C, C-4”-OCH3), 59.4 
(1C, C-2”-OCH3), 55.4 (1C, C-1-OCH3), 21.2, 20.9 (2C, 2 x 
Ac-CH3) ppm; MS (ESI-TOF): m/z calcd for C65H76NaO18: 
1167.4924 [M+Na]
+
; found: 1167.4885. 
Methyl (6-O-benzyl-2,3,4-tri-O-methyl-α-D-
glucopyranosyl)-(1→4)-[2,3-di-O-acetyl-6-O-(2-
naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-(2,3,6-tri-O-
benzyl-α-D-glucopyranosyl)-(1→4)-[2,3-di-O-methyl-6-O-
(2-naphthyl)methyl-α-L-idopyranosyl]-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (25). To a solution of 
trisaccharide acceptor 21a (38 mg, 0.031 mmol) and disaccha-
ride donor 22
32
 (37 mg, 0.047 mmol, 1.5 equiv.) in dry CH2Cl2 
(1.2 mL) 4 Å MS (250 mg) were added and the reaction mix-
ture was stirred at room temperature. After 30 min the stirred 
 mixture was cooled to −20 °C under argon. After at this tem-
perature, NIS (16 mg, 0.070 mmol, 1.5 equiv. to the donor) 
and TfOH (2.0 µL, 0.020 mmol, 0.3 equiv. to the NIS) dis-
solved in dry THF (28 µL) were added. The temperature was 
allowed to warm up to +5 °C and the reaction mixture was 
stirred for 4 h. Than reaction mixture was quenched with Et3N 
(150 µL), diluted with CH2Cl2 (25 mL), filtered and the mix-
ture was washed with saturated aqueous solution of Na2S2O3 
(2 x 5 mL), saturated aqueous solution of NaHCO3 (5 mL) and 
H2O (2 x 5 mL) until neutral pH. The organic layer was dried 
on MgSO4 and concentrated. The crude product was purified 
by silica gel chromatography (55:45 n-hexane/EtOAc to 1:1 n-
hexane/EtOAc) to give 25 (41 mg, 70%) as a colourless syrup. 
[α]D
25
 +60.0 (c 0.10, CHCl3); Rf 0.45 (1:1 n-hexane/EtOAc); 
1
H NMR (CDCl3, 500 MHz) δ 7.77-7.07 (m, 49H, arom), 5.22 
(d, J = 3.7 Hz, 1H, H-1-F), 5.09-5.05 (m, 2H, H-1-D, H-3-E), 
4.97-4.95 (m, 2H, 2 x Bn-CH2a), 4.89 (d, J = 6.9 Hz, 1H, H-1-
G), 4.82 (t, J = 8.3 Hz, 1H, H-2-E), 4.80-4.25 (m, 18H, H-1-H, 
H-1-E, 2 x NAP-CH2, 2 x Bn-CH2b, 5 x Bn-CH2), 4.05 (dd, J = 
5.0 Hz, J = 9.7 Hz, 1H, H-5-G), 3.95-3.84 (m, 5H, H-3-H, H-
4-E, H-4-F, H-4-G, H-4-H), 3.79-3.68 (m, 7H, H-3-F, H-5-F, 
H-5-H, H-6a-F, H-6a-G, H-6a,b-H), 3.67-3.61 (m, 4H, H-3-G, 
H-6b-G, H-6a,b-E), 3.60-3.55 (m, 4H, H-5-D, C-3-D-OCH3), 
3.50-3.44 (m, 10H, H-2-F, H-2-H, H-6b-F, H-6a-D, C-2-G-
OCH3, C-3-G-OCH3), 3.43-3.39 (m, 8H, H-3-D, H-6b-D, C-2-
D-OCH3, C-3-D-OCH3), 3.34 (s, 3H, C-1-H-OCH3), 3.20-3.15 
(m, 2H, H-4-D, H-5-E), 3.06-3.00 (m, 2H, C-2-D, H-2-G), 
2.00, 1.82 (2 x s, 6H, 2 x Ac-CH3) ppm; 
13
C NMR (CDCl3, 
125 MHz) δ 170.1, 169.7 (2C, 2 x Ac-CH3), 139.6, 139.5, 
138.6, 138.5, 138.3, 138.2, 137.7, 136.2, 135.9, 133.4, 133.9 
(13C, 13 x Cq arom), 128.9-125.8 (49C, arom), 100.0 (1C, C-
1-E), 99.8 (1C, C-1-G), 98.6 (1C, C-1-F), 98.4 (1C, C-1-H), 
97.9 (1C, C-1-D), 84.5 (1C, C-2-G), 83.3 (1C, C-3-D), 82.2 
(1C, C-3-G), 81.9 (1C, C-2-D), 80.3 (1C, C-3-H), 80.0 (1C, C-
3-F), 79.5 (1C, C-2-H), 79.4 (1C, C-4-D), 79.0 (1C, C-2-F), 
76.8 (1C, C-4-F), 76.6 (1C, C-4-H), 76.5 (1C, C-4-G), 75.5 
(1C, NAP-CH2), 75.3, (1C, C-3-E), 75.2 (1C, C-5-E), 75.0 
(1C, NAP-CH2), 74.9 (1C, C-4-E), 73.8, 73.7, 73.4, 73.3, 73.1 
(7C, 7 x Bn-CH2), 72.9 (1C, C-2-E), 72.2 (1C, C-5-G), 71.3 
(1C, C-5-D), 71.0 (1C, C-5-F), 70.5 (1C, C-5-H), 68.9 (1C, C-
6-G), 68.8 (1C, C-6-E), 68.5 (1C, C-6-D), 68.3 (1C, C-6-H), 
67.6 (1C, C-6-F), 60.8 (1C, C-3-D-OCH3), 60.5 (2C, C-3-G-
OCH3, C-4-D-OCH3), 60.3 (1C, C-2-G-OCH3), 59.3 (1C, C-2-
D-OCH3), 55.4 (1C, C-1-H-OCH3), 21.1, 20.8 (2C, 2 x Ac-
CH3) ppm; MS (MALDI-TOF): m/z calcd for C111H126NaO28: 
1931.190 [M+Na]
+
; found: 1931.124; Elemental analysis calcd 
(%) for C111H126O28: C, 69.87; H, 6.66; found: C, 69.96; H, 
6.74. 
Methyl (6-O-benzyl-2,3,4-tri-O-methyl-α-D-
glucopyranosyl)-(1→4)-[6-O-(2-naphthyl)methyl-β-D-
glucopyranosyl]-(1→4)-(2,3,6-tri-O-benzyl-α-D-
glucopyranosyl)-(1→4)-[2,3-di-O-methyl-6-O-(2-
naphthyl)methyl-α-L-idopyranosyl]-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (26). Compound 25 (33 mg, 
0.017 mmol) was dissolved in MeOH (1.0 mL) and NaOMe 
was added (5 mg, 0.092 mmol, pH ≈ 10) and the reaction 
mixture was stirred at room temperature for 24 h. Than the 
reaction mixture was neutralized by Amberlite IR-120 (H
+
) 
ion-exchange resin, filtrated, washed with MeOH and concen-
trated. The crude product was purified by column chromatog-
raphy (65:35 = n-hexane/acetone) to give 26 (25 mg, 78 %) as 
a colourless syrup. [α]D
25
 +55.0 (c 0.06, CHCl3); Rf 0.29 (7:3 
n-hexane/acetone); 
1
H NMR (CDCl3, 500 MHz) δ 7.77-7.13 
(m, 49H, arom), 5.22 (d, J = 3.7 Hz, 1H, H-1-F), 5.03 (d, J = 
3.5 Hz, 1H, H-1-D), 4.96 (d, J = 5.9 Hz, 1H, H-1-G), 4.95-
4.28 (m, 20H, H-1-H, H-1-E, 2 x NAP-CH2, 7 x Bn-CH2), 
4.00-3.96 (m, 2H, H-4-F, H-5-G), 3.90-3.82 (m, 3H, H-3-F, H-
4-G, H-6a-F), 3.79-3.65 (m, 9H, H-3-H, H-3-G, H-4-H, H-5-
H, H-5-F, H-6a,b-H, H-6a,b-G), 3.61 (s, 3H, C-3-D-OCH3), 
3.59-3.57 (m, 1H, H-5-D), 3.56 (s, 3H, C-2-D-OCH3), 3.54-
3.50 (m, 2H, H-3-E-OH, H-6a-E), 3.48 (s, 4H, H-2-F, C-3-G-
OCH3), 3.47-3.40 (m, 13H, H-2-H, H-3-D, H-3-E, H-4-E, H-
6a-D, H-6b-F, H-6b-E, C-2-G-OCH3, C-4-D-OCH3), 3.36 (s, 
3H, C-1-H-OCH3), 3.33-3.29 (m, 2H, H-2-E, H-6b-D), 3.22 (s, 
1H, C-2-E-OH), 3.19-3.13 (m, 3H, H-2-D, H-4-D, H-5-E), 
3.05-3.02 (m, 1H, H-2-G) ppm; 
13
C NMR (CDCl3, 125 MHz) 
δ 139.5, 138.6, 138.4, 138.1, 137.7, 136.4, 136.0, 133.4, 133.0, 
132.9 (13C, 13 x Cq arom), 128.6-125.8 (49C, arom), 103.1 
(1C, C-1-E), 100.6 (1C, C-1-D), 100.0 (1C, C-1-G), 98.5 (1C, 
C-1-H), 98.3 (1C, C-1-F), 84.7 (1C, C-2-G), 84.1 (1C, C-3-D), 
82.9 (1C, C-2-D), 82.5 (1C, C-3-G), 82.0 (1C, C-4-E), 80.6 
(1C, C-3-F), 80.3 (1C, C-3-H), 79.5 (2C, C-2-H, C-4-D), 79.4 
(1C, C-2-F), 76.7 (2C, C-4-F, C-4-H), 76.3 (1C, C-4-G), 76.1 
(1C, C-3-E), 75.3, 74.8 (2C, 2 x NAP-CH2), 74.7, (1C, C-5-E), 
74.0 (1C, C-2-E), 73.7, 73.6, 73.4, 73.3, 72.9 (7C, 7 x Bn-
CH2), 72.0 (1C, C-5-G), 71.4 (1C, C-5-D), 70.8 (1C, C-5-F), 
70.5 (1C, C-5-H), 69.3 (1C, C-6-G), 69.0 (1C, C-6-E), 68.5 
(2C, C-6-D, C-6-H), 68.3 (1C, C-6-F), 60.9 (1C, C-3-D-
OCH3), 60.6 (1C, C-4-D-OCH3), 60.3 (3C, C-2-G-OCH3, C-3-
G-OCH3, C-2-D-OCH3), 55.4 (1C, C-1-H-OCH3) ppm; MS 
(MALDI-TOF): m/z calcd for C107H122NaO26: 1845.812 
[M+Na]
+
; found: 1845.714; Elemental analysis calcd (%) for 
C107H122O26: C, 70.45; H, 6.74; found: C, 70.51; H, 6.80. 
Methyl (6-O-benzyl-2,3,4-tri-O-methyl-α-D-
glucopyranosyl)-(1→4)-[2,3-di-O-methyl-6-O-(2-
naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-(2,3,6-tri-O-
benzyl-α-D-glucopyranosyl)-(1→4)-[2,3-di-O-methyl-6-O-
(2-naphthyl)methyl-α-L-idopyranosyl]-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (27). To a solution of 26 (21 
mg, 0.0115 mmol) in dry DMF (250 µL) was added NaH 
(60%, 10 mg, 0.250 mmol) at 0 °C. After stirring for 30 min at 
0 °C, MeI (20 µL, 0.321 mmol) was added and stirred for 24 h 
at room temperature. When complete conversion of the start-
ing material into a main spot had been observed by TLC anal-
ysis, CH3OH (500 µL) was added. The reaction mixture was 
stirred for 5 min and the solvents were evaporated. The resi-
due was dissolved in CH2Cl2 (25 mL), and washed with H2O 
(2 x 5.0 mL), the organic layer was filtered, dried and evapo-
rated. The crude product was purified by silica gel chromatog-
raphy (6:4 = n-hexane/acetone) to give 27 (16 mg, 80%) as a 
colourless syrup. [α]D
25
 +45.7 (c 0.07, CHCl3); Rf 0.58 (6:4 n-
hexane/acetone); 
1
H NMR (CDCl3, 500 MHz) δ 7.78-7.08 (m, 
49H, arom), 5.58 (d, J = 3.7 Hz, 1H), 5.23 (d, J = 3.6 Hz, 1H), 
5.02-4.06 (m, 21H, 3 x H-1, 7 x Bn-CH2, 2 x NAP-CH2), 4.06 
(dd, J = 4.7 Hz, J = 9.6 Hz, 1H), 3.98 (t, J = 9.4 Hz, 1H), 3.89-
3.62 (m, 17H), 3.62-3.32 (m, 4H), 3.60, 3.54, 3.48, 3.45, 3.38, 
3.36, 3.33 (7 x s, 24H, 8 x OCH3), 3.29-3.21 (m, 4H), 3.15 
(dd, J = 3.7 Hz, J = 9.8 Hz, 1H), 3.04-3.00 (m, 1H), 2.94-2.91 
(m, 1H) ppm; 
13
C NMR (CDCl3, 125 MHz) δ 139.7, 139.4, 
138.6, 138.4, 138.2, 138.0, 136.5, 135.9, 133.4, 133.0, 132.9 
(13C, 13 x Cq arom), 128.7-125.7 (49C, arom), 102.9, 100.0, 
98.5, 96.3 (5C, 5 x C-1), 86.7, 84.7, 84.6, 83.6, 82.4, 81.9, 
80.4, 79.9, 79.5, 79.4, 79.0, 77.0, 76.7, 76.2, 74.8, 72.4, 72.2, 
71.4, 70.9, 70.5 (20C skeleton carbons), 75.6, 74.9, 73.8, 73.5, 
73.4, 73.3, 73.2 (9C, 2 x NAP-CH2, 7 x Bn-CH2), 69.4, 68.3, 
68.2, 67.8 (5C, 5 x C-6), 60.9, 60.5, 60.3, 59.8, 59.6 (7C, 7 x 
 OCH3), 55.4 (1C, C-1-H-OCH3) ppm; MS (MALDI-TOF): 
m/z calcd for C109H126NaO26: 1873.843 [M+Na]
+
; found: 
1873.749; Elemental analysis calcd (%) for C109H126O26: C, 
70.68; H, 6.86; found: C, 70.73; H, 6.91. 
Methyl (6-O-benzyl-2,3,4-tri-O-methyl-α-D-
glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-
glucopyranosyl)-(1→4)-(2,3,6-tri-O-benzyl-α-D-
glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-
idopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (28). To a vigorously stirred solution of 27 
(14 mg, 0.007 mmol) in CH2Cl2 (2.0 mL) and H2O (250 µL), 
DDQ (5.0 mg, 0.021 mmol) was added. After 30 min the 
mixture was diluted with CH2Cl2 (20 mL) and extracted with 
saturated aqueous NaHCO3 (2 x 5 mL) and H2O (2 x 5 mL), 
dried and concentrated. The crude product was purified by 
silica gel chromatography (6:4 n-hexane/acetone) to give 28 (8 
mg, 71%) as a colourless syrup. [α]D
25
 +61.4 (c 0.08, CH2Cl2); 
Rf 0.52 (6:4 n-hexane/acetone); 
1
H NMR (CDCl3, 360 MHz) δ 
7.39-7.18 (m, 35H, arom), 5.52 (d, J = 3.7 Hz, 1H), 5.15 (d, J 
= 3.4 Hz, 1H), 4.93-4.50 (m, 16H, 7 x Bn-CH2, 2 x H-1), 4.28 
(d, J = 7.8 Hz, 1H), 3.93-3.63 (m, 15H), 3.62-3.15 (m, 12H), 
3.61, 3.58, 3.54, 3.49, 3.44, 3.42, 3.39, 3.35 (8 x s, 24H, 8 x 
OCH3), 3.03-2.94 (m, 3H), 2.36, 2.08 (2 x s, 2H, 2 x OH) 
ppm; 
13
C NMR (CDCl3, 90 MHz) δ 138.7, 138.4, 138.0, 137.8, 
137.7, 137.5, 137.4 (7C, 7 x Cq arom), 128.2-127.3 (35C, 
arom), 102.3, 98.6, 97.8, 97.0, 96.3 (5C, 5 x C-1), 86.1, 84.4, 
83.1, 82.6, 81.5, 81.4, 80.1, 79.6, 79.2, 78.4, 75.2, 74.1, 73.9, 
71.2, 70.8, 70.6, 70.1 (20C, skeleton carbons), 75.5, 74.9, 
73.2, 73.1, 72.7 (7C, 7 x Bn-CH2), 68.1, 68.0, 67.4, 61.6 (5C, 
5 x C-6), 60.4, 60.1, 60.0, 59.6, 59.4, 59.3, 59.2 (7C, 7 x 
OCH3), 54.9 (C-1-H-OCH3) ppm; MS (MALDI-TOF): m/z 
calcd for C87H110NaO26: 1593.72 [M+Na]
+
; found: 1593.81; 
Elemental analysis calcd (%) for C87H110O26: C, 66.48; H, 
7.05; found: C, 66.56; H, 7.11. 
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ABBREVIATIONS 
AT, antithrombin; DDQ, 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone; Np, 2-naphthyl; NAP, (2-naphthyl)methyl; 
TBDPS, tert-butyldiphenylsilyl;TLC, thin layer chromatography. 
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